fashion -WSS

fashion

author：hotspot 2025-09-30 22:03:54 - browse：2389

Zepbound, a injectable drug on a gradient background of dark purple and green — biotech coverage from STAT — Illustration: STAT; Source: Eli Lilly/AP

Eli Lilly’s blockbuster diabetes and obesity drug improved living scarring in a mid-stage study of the liver disease MASH, adding to positive data announced earlier this year.

The study tested three doses of tirzepatide, sold commercially as Mounjaro or Zepbound. The percentage of patients who experienced a greater than one-stage improvement in scarring, or fibrosis, without worsening of their disease was 54.9%, 51.3%, and 51.0% from the lowest to highest doses.

When compared with the 29.7% of patients on placebo who achieved this outcome, the results were statistically significant, according to an abstract of data that will be presented at the annual meeting of the European Association for the Study of the Liver.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： Intarcia’s device

knowledge

WSS

Hearing on Medicare drug price negotiation gets unusually heated

Senate HELP committee spars over health care workforce policies

How Vertex's cystic fibrosis drug is changing patients' lives

AstraZeneca loses challenge to Medicare drug price negotiation

FogPharma raises $145 million in rare Series E round

Experts study whether long Covid risk adds up with each reinfection

Wikipedia

fashion

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

DIEP, the 'gold standard' of breast reconstruction, is under threat

CDC's new outbreak response network to include Northeastern

Drug repurposing or repositioning? The language matters

Kristina Burow of ARCH Venture Partners shares her next big bets STAT

How one medical school became remarkably diverse

Intarcia’s device

23andMe had bad news about my health. I wish a person had delivered it

An inside look at PIPEs, biotech's buzzy new financing tool

Virginia high school admissions case could be legal follow

Senate HELP committee spars over health care workforce policies

Wikipedia

Change Healthcare cyberattack outage could last weeks

International team creates first chimeric human

Senate HELP committee spars over health care workforce policies

ALS groups 'won't be played again' by the FDA, drug sponsors

EpiPen alternative approval delay highlights citizen petition issue

CommonSpirit Health keeps growing, even as it loses money

hotspot

knowledge

leisure time

leisure time